SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is trending as heightened speculation around a potential buyout and unconfirmed M&A rumors drive significant after-hours volume and price volatility. Community members are actively debating the legitimacy of these reports, with long-term shareholders analyzing historical valuation metrics and potential takeover scenarios while others speculate on the motivations behind recent unusual trading patterns.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

The Veil community is rallying around the project's focus on digital privacy and decentralization, often citing its multi-algorithm mining and staking capabilities as key differentiators. Investors are actively discussing the potential for a privacy-focused market surge, frequently highlighting the project's long-term utility alongside established privacy coins.

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

Blue Owl Capital is trending due to significant liquidity concerns following the restricted withdrawal access in its private credit funds, which has sparked investor anxiety over potential sector-wide fallout. The community is actively debating whether this represents an isolated incident or a broader 'canary in the coal mine' moment for private credit stability amidst rising default risks.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

Investors are closely monitoring YETH as the community debates its weekly distribution payouts versus the underlying volatility of Ethereum. While some traders leverage the fund for its income potential during range-bound market phases, others remain cautious due to concerns regarding NAV erosion and management performance.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is currently a focal point for intense debate, as investors weigh ongoing regulatory developments like the Clarity Act against sentiment that the project is facing a long-term decline. While some community members view the current price as a prime accumulation opportunity for the long term, others are actively pivoting toward Bitcoin or expressing frustration over what they perceive as stagnant institutional interest and stalled performance.

ARK ETF Trust - ARK Autonomous Technology & Robotics ETF

ARK Autonomous Technology & Robotics ETF

ARKQ is capturing investor attention as community members debate whether emerging robotics and 'embodied AI' infrastructure will take the tech sector's leadership baton this year. The ETF remains a focal point for discussion regarding portfolio rotation into automation themes, with sentiment driven by institutional buying activity and the sector's long-term growth potential.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

ChainLink is trending as investors debate its long-term infrastructure value versus recent price consolidation, with community sentiment split between frustration over sluggish performance and high conviction in its role as a backbone for real-world asset tokenization. Many are actively discussing potential catalysts like upcoming regulatory clarity and institutional partnerships that they believe will eventually drive a significant supply-side squeeze.

ARK ETF Trust - ARK Innovation ETF

ARK Innovation ETF

Investors are closely watching the ARK Innovation ETF as it experiences sharp volatility, with community members expressing polarized views on Cathie Wood's aggressive buying and selling patterns amid broader market rotation out of high-beta growth stocks. The ongoing discourse highlights concerns over the fund's long-term performance and its heavy exposure to volatile tech and crypto-linked assets, leading to intense debates between those betting on an innovation-led rebound and those skeptical of the fund's strategy.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie Inc. is trending as investors weigh strong Q4 earnings, highlighted by robust sales growth in its immunology portfolio, against concerns over Humira's declining revenue and broader pharmaceutical sector volatility. The community is actively discussing the stock's long-term growth potential and M&A prospects, specifically focusing on the company's aggressive search for obesity drug assets to compete in the weight-loss market.

SLB Ltd. engages in the provision of energy technology. It operates through the following business segments: Digital, Reservoir Performance, Well Construction, Production Systems, and All Other. The Digital segment involves the combination of digital solutions and data products with its Asset Performance Solutions. The Reservoir Performance segment consists of technologies and services for productivity and performance optimization. The Well Construction segment includes the full portfolio of products and services for well placement and performance, drilling, and wellbore assurance. The Production Systems segment focuses on the development of technologies and provides services to production and recovery from subsurface reservoirs to the surface, into pipelines, and refineries. The company was founded by Conrad Schlumberger and Marcel Schlumberger in 1926 and is headquartered in Houston, TX.

SLB Ltd.

Schlumberger Ltd.

Schlumberger is trending as investors focus on its pivotal role in the potential revival of Venezuela's energy sector following recent geopolitical shifts. Community sentiment is mixed, with long-term holders emphasizing the company's critical technical expertise in oilfield services while short-term traders closely monitor price consolidation and volatility ahead of upcoming earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The&nbsp;company&nbsp;opened nine new stores and closed five stores during fiscal 2025.</li><li>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025.</li><li>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares.</li></ul><p>Shares of J. Jill (JILL) slumped 26% on Tuesday after it reported a 3.1% decline in its fourth quarter net sales.&nbsp;</p><p>Net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million compared to $142.8 million for the fourth quarter of fiscal 2024, it said. Analysts expected revenue of $135.5 million as per data from Stocktwits.&nbsp;</p><p>JILL reported adjusted net loss per diluted share in the fourth quarter of fiscal 2025 at $0.02 compared to adjusted net income per diluted share of $0.32 in the fourth quarter of fiscal 2024.</p><p>The company opened nine new stores and closed five stores during fiscal 2025, ending the year with 256 stores compared to 252 stores at the end of fiscal 2024.</p><h2 class="st-heading-2">Analyst Rationale</h2><p>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares following the company’s earnings report. The analyst told investors in a note that J.Jill delivered Q4 results "above a low bar," but "more importantly" FY26 guidance came in well below Street expectations, driven by cautious demand assumptions and incremental tariff headwinds.</p><p>BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.</p><h2 class="st-heading-2">Outlook</h2><p>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025. Analysts expected revenue for the quarter at $155.65 million, as per Stocktwits.&nbsp;</p><p>For the full year of fiscal 2026, the company expects net sales to be flat to down 2% compared to fiscal 2025.</p><p>JILL said that the outlook assumes an average 20% reciprocal tariff rate on applicable inventory received prior to February 28, 2026, an average 10% reciprocal tariff rate on applicable inventory received after February 28, 2026 through the first quarter of fiscal 2026, and an average 15% reciprocal tariff rate thereafter.&nbsp;</p><h2 class="st-heading-2">Retail Reaction</h2><p>Retail sentiment around JILL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company are down 19% so far in 2026.&nbsp;</p><p>&nbsp;</p>

BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.

J. Jill Stock Slumps 26% Today – Why Such A Selloff?

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 

Equity

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 


<ul class="summary-bullets"><li>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</li><li>The company said that its gross margin for Q4 was at 13.4%, compared to gross margin of 15.3% from year-ago.&nbsp;</li><li>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</li></ul><p>FreightCar America shares slumped 19% during extended hours of trading on Monday as it reported a decline in its fourth quarter revenue.&nbsp;</p><p>The company said its revenues in Q4 came at $125.6 million,&nbsp;lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period.&nbsp;</p><p>The revenue fell well short of analyst estimates of $144.95 million, according to data from Fiscal.ai.&nbsp;</p><h2 class="st-heading-2">Q4 Snapshot</h2><p>The company posted a fall in its profit in Q4. It reported adjusted net income of $4.9 million, or $0.16 per share, compared to $0.21 per share from the year-ago quarter. RAIL also missed profit expectations of $0.19 per share, as per Fiscal.ai.&nbsp;</p><p>“In 2025, FreightCar America executed with discipline amid a challenging industry environment, delivering revenue in line with our expectations while producing exceptional profitability,” said Nick Randall, President and Chief Executive Officer of FreightCar America.</p><p>The company said that its gross margin was at 13.4% with gross profit of $16.8 million, compared to gross margin of 15.3% with gross profit of $21.0 million in the fourth quarter of 2024.&nbsp;</p><h2 class="st-heading-2">Outlook</h2><p>The company said it expects FY 2026 revenue of $500 million to $550 million. However, it fell way short of Wall Street expectations of $625.65 million.&nbsp;</p><p>“As we enter 2026, we remain focused on converting backlog into profitable deliveries while continuing to invest for growth,” Randall said.&nbsp;</p><p>“Looking ahead to 2026, our guidance reflects ongoing industry uncertainty while reinforcing our confidence in the underlying strength and resilience of the business,” said Mike Riordan, Chief Financial Officer of FreightCar America.&nbsp;</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment around RAIL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;</p><p>Shares in the company have fallen nearly 11% so far in 2026.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Freightcar Americs said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024. 

FreightCar America Slumps 21% As Q4 Results And FY26 Disappoints Investors

The company said its revenues in Q4 came at $125.6 million, lower than $137.7 million in the fourth quarter of 2024, despite railcar deliveries of 1,172 units compared to 1,019 units in the prior year period. 

Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?

Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization.</li><li>The company said following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs.</li><li>Seres noted that its cost-cutting measures are expected to extend its cash runway into the third quarter of 2026.</li></ul><p>Seres Therapeutics Inc. (MCRB) shares fell more than 21% in Thursday’s pre-market trade after the company announced that it is pausing a planned Phase 2 study, while reducing the headcount by 30% to extend its cash runway.</p><p>Seres stated that it has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the U.S. Food and Drug Administration (FDA).</p><p>“As we pursue earlier stage programs with the greatest opportunity, such as those targeting inflammatory bowel disease (IBD), we are exploring collaborations to provide additional capital to the company,” said Thomas DesRosier and Marella Thorell, co-CEOs of Seres.</p><h2 class="st-heading-2">Why Did Seres Pause The Study?</h2><p>Seres said the pause follows the completion of study site evaluation and qualification work with its contract research organization, adding that the Phase 2 study drug substance has already been manufactured.</p><p>The company said that following the pause in additional investment into the SER-155 Phase 2 study, it will shift its operational focus to high-value earlier-stage pipeline programs. At the same time, it will continue to seek funding for the Phase 2 study, Seres said.</p><h2 class="st-heading-2">Extending Cash Runway</h2><p>Seres noted that its cost-cutting measures, including workforce reductions, are expected to extend its cash runway into the third quarter (Q3) of 2026.</p><p>The company said that this will help in supporting the continued development of its programs for inflammatory and immune-related diseases, while also giving it additional time to secure funding for the SER-155 Phase 2 study.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/MCRB">Seres Therapeutics</a> trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘high’ levels.</p><p>One user on Stocktwits said that Seres’ announcement confirms that “there is no one interested to partner” with the company.</p><p><stembedurl>https://stocktwits.com/Kenny1207/message/644771398</stembedurl></p><p><a href="https://stocktwits.com/symbol/MCRB">MCRB stock</a> is down 51% year-to-date and 75% over the past 12 months.</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/samsung-ships-world-first-commercial-hbm4-memory-module-ai-computing/cZRTlXNR4ra"><strong>Samsung Ships First Commercial HBM4 Memory Module, Nvidia’s Vera Rubin Expected To Use It: SSNLF Stock Soars 55%</strong></a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Seres Therapeutics biotechnology company building, Cambridge, Massachusetts, USA

MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30%

The company said that it will continue to seek funding for the SER-155 Phase 2 study.

Small-Cap ETFs Rally in July: Will the Momentum Continue?

Small-cap ETFs like AVSC, XSVM, BBSC, SVAL and EES are soaring in July, fueled by rate cut hopes, deep discounts and sector rebounds.


WisdomTree Trust - WisdomTree U.S. SmallCap Fund

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

EES
WisdomTree Trust - WisdomTree U.S. SmallCap Fund

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest EES News

EESWisdomTree Trust - WisdomTree U.S. SmallCap Fund